Matinas BioPharma Holdings, Inc. (MTNB) · Nov 3, 2026 · Agreement terminated
$562,500 advisor payout — $562,500 cash paid; prior agreement allowed up to $2.0M cash plus $2.0M stock
Matinas terminated a former advisor agreement and paid $562,500 in cash, trimming one obligation but adding another cash drain during its GH Power transition.
Matinas is no longer primarily a clinical-stage biotech story: it has paused MAT2203 development, agreed to sell that platform, and is pursuing a reverse-merger-style combination with GH Power to create a clean-energy company. Its latest filing also warned that existing cash was insufficient to fund operations for the next twelve months, making cash outflows more consequential.
The filing closes out one advisor relationship, but it does not cancel the larger transaction. Matinas said it and a former financial advisor terminated their agreement and exchanged mutual releases. Nothing in the disclosure says the GH Power business combination itself has been terminated or materially changed.
The immediate effect is a cash cost during a cash-constrained transition. Matinas paid the advisor $562,500 in cash, while the old agreement had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business-combination closings. That may eliminate a larger contingent-fee exposure, but the filing does not quantify what amount, if any, was avoided.
Relative to the standing story, this is a small complication rather than a strategic reset. The termination adds a definite cash drain and introduces uncertainty around the advisor's role in the transaction process, but it leaves the main value-bearing catalyst—the expected GH Power combination—unchanged on the face of this filing.
Bottom line: Matinas paid to end a former advisor relationship while still trying to complete its GH Power transition. It modestly worsens the near-term cash picture, but does not by itself change the core transaction story.
GH Power business combination, expected Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!